PO:31:161 | First-line diagnostic tests to intercept primary heart involvement in systemic sclerosis: clinical associations from the SPRING-SIR registry
Antonio Tonutti1|2, Francesca Motta1|2, Rossella De Angelis3, Valeria Riccieri4, Silvia Laura Bosello5, Fabio Cacciapaglia6, Veronica Codullo7, Giacomo De Luca8, Francesca Ingegnoli9, Dilia Giuggioli10, Clodoveo Ferri10, Marco Matucci-Cerinic8, Carlo Selmi1|2, Maria De Santis1|2 | 1Department of Biomedical Sciences, Humanitas University Pieve Emanuele, Milan, Italy; 2Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital Rozzano, Milan, Italy; 3Università Politecnica delle Marche Ancona, Italy; 4Università degli Studi di Roma La Sapienza Roma, Italy; 5Università Cattolica del Sacro Cuore Roma, Italy; 6Università degli Studi di Bari Aldo Moro Bari, Italy; 7Reumatologia, Fondazione IRCCS Policlinico San Matteo Pavia, Italy; 8Università Vita-Salute San Raffaele Milano, Italy; 9Università degli Studi di Milano, Italy; 10Università degli Studi di Modena e Reggio Emilia, Italy
Abstract
Background. Primary heart involvement (pHI) is an overlooked, poorly characterized complication of systemic sclerosis (SSc), associated with worse prognosis. To fill the gap in the literature, this study evaluates the risk factors for first level assessment, specifically ECG and echocardiographic alterations suggestive of SSc-pHI in the nationwide SPRING cohort. Materials and methods This was a retrospective, multicenter, cohort study. Out of 1922 SSc patients in SPRING, we excluded those with confounding cardiac conditions according to WSF/HFA (arterial hypertension, diabetes, ischemic heart disease, pulmonary disease, PAH, echocardiographic PASP >/= 40mmHg, renal impairment, scleroderma renal crisis), and those with incomplete ECG/echocardiographic assessment. Cross-sectional and longitudinal analyses were performed to identify risk factors for SSc-pHI, defined as the presence of at least one of the following domains: non-ischemic hypokinesia; left ventricle (LV) dilatation; diastolic dysfunction; arrhythmias; conduction blocks.
Results. Of 600 eligible patients, 90% were females, with a median age at SSc onset of 45 (IQR 35-55) and disease duration of 8 years (4-14); 22% had dcSSc, 43% ILD, 24% digital ulcers, 16% muscle weakness, 6.5% muscle atrophy, 53% esophageal and 22% intestinal involvement. Anti-Scl70 were positive in 41%, ACA in 39%. At baseline, 149 (25%) had signs of SSc-pHI. Diastolic dysfunction was the most common alteration (62%), followed by conduction block (34%), arrhythmia (11%), LV dilation (9%), and hypokinesia (3%). The alterations were not mutually exclusive. Weak but significant correlations were found between increasing PASP and arrhythmia, increasing PASP and diastolic dysfunction, and LV dilation and non-ischemic hypokinesia; diastolic dysfunction negatively correlated with LV dilation and arrhythmia (Figure 1). In the multivariable logistic regression (adjusted for age, sex, and duration), the risk of SSc-pHI was increased with dcSSc (OR 1.85; 95%CI 1.05-3.26), intestinal symptoms (OR 1.79; 95%CI 1.03-3.08), and age at SSc onset (OR 1.04; 95%CI: 1.02-1.06) (Table 1). During follow-up (data available for 125 subjects), 31 new SSc-pHI cases were recorded (cumulative incidence 25%). Overall mortality did not differ between patients with or without incident SSc-pHI. Cox proportional hazards regression (adjusted for age, duration, and sex) revealed muscle atrophy as the only risk factor for new-onset SSc-pHI (HR 2.83, 95%CI 1.01-7.73) (Table 2). Exposure to immunosuppressive and vasoactive treatments did not differ between patients with or without SSc-pHI.
Conclusions. pHI is a protean and severe complication possibly affecting one-quarter of SSc cases. Early detection is crucial, and patients older at disease onset, with the diffuse form, muscular involvement, and intestinal manifestations can be those at higher risk.
Results. Of 600 eligible patients, 90% were females, with a median age at SSc onset of 45 (IQR 35-55) and disease duration of 8 years (4-14); 22% had dcSSc, 43% ILD, 24% digital ulcers, 16% muscle weakness, 6.5% muscle atrophy, 53% esophageal and 22% intestinal involvement. Anti-Scl70 were positive in 41%, ACA in 39%. At baseline, 149 (25%) had signs of SSc-pHI. Diastolic dysfunction was the most common alteration (62%), followed by conduction block (34%), arrhythmia (11%), LV dilation (9%), and hypokinesia (3%). The alterations were not mutually exclusive. Weak but significant correlations were found between increasing PASP and arrhythmia, increasing PASP and diastolic dysfunction, and LV dilation and non-ischemic hypokinesia; diastolic dysfunction negatively correlated with LV dilation and arrhythmia (Figure 1). In the multivariable logistic regression (adjusted for age, sex, and duration), the risk of SSc-pHI was increased with dcSSc (OR 1.85; 95%CI 1.05-3.26), intestinal symptoms (OR 1.79; 95%CI 1.03-3.08), and age at SSc onset (OR 1.04; 95%CI: 1.02-1.06) (Table 1). During follow-up (data available for 125 subjects), 31 new SSc-pHI cases were recorded (cumulative incidence 25%). Overall mortality did not differ between patients with or without incident SSc-pHI. Cox proportional hazards regression (adjusted for age, duration, and sex) revealed muscle atrophy as the only risk factor for new-onset SSc-pHI (HR 2.83, 95%CI 1.01-7.73) (Table 2). Exposure to immunosuppressive and vasoactive treatments did not differ between patients with or without SSc-pHI.
Conclusions. pHI is a protean and severe complication possibly affecting one-quarter of SSc cases. Early detection is crucial, and patients older at disease onset, with the diffuse form, muscular involvement, and intestinal manifestations can be those at higher risk.
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.